Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels
1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50–300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical sta...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 1990, Vol.14 (1), p.25-35 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 25 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 14 |
| creator | Altamura, Carlo A. Colacurcio, Fulgenzio Kauri, Massimo C. Moro, Anna R. De Novellis, Fedele |
| description | 1.
1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50–300 mg i.m. monthly dose) for 12 months.
2.
2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population.
3.
3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1).
4.
4. A positive correlation was found between the administered dose and haloperidol plasma levels.
5.
5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1.
6.
6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses. |
| doi_str_mv | 10.1016/0278-5846(90)90061-K |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79603631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>027858469090061K</els_id><sourcerecordid>79603631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-e224ffec555df90aa8befdfe4ca60e712edb98f60d4f811baf988a47cfac8dc53</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJSTdp_0ELOoSSHNxK_pDlHAoh5KMk0EtLj2J2NMIKsuVI3pT019fbXdJbTwPzPjO8PIy9l-KTFFJ9FmWri0bX6rQTZ50QShZ3r9hK6mVdl1IdsNUL8oYd5fwghJCVqA7ZoexUq-t2xX7eQogTJW9j4JYQxggzcT9y7FMcPfKMvf8dpz7R6OGcX_A8b-wzj47Lkg9xnPvMf_m551OAPAAP9EQhv2WvHYRM7_bzmP24vvp-eVvcf7v5enlxX2Cl1VxQWdbOETZNY10nAPSanHVUIyhBrSzJrjvtlLC101KuwXVaQ92iA9QWm-qYfdz9nVJ83FCezeAzUggwUtxk03ZKVKqSC1jvQEwx50TOTMkPkJ6NFGbr02xlma0s0wnz16e5W84-7P9v1gPZf0c7gUt-ss8hIwSXYESfXzDVVmUptjW_7LBFDT15SiajpxHJ-kQ4Gxv9_3v8AYQlkxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79603631</pqid></control><display><type>article</type><title>Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Altamura, Carlo A. ; Colacurcio, Fulgenzio ; Kauri, Massimo C. ; Moro, Anna R. ; De Novellis, Fedele</creator><creatorcontrib>Altamura, Carlo A. ; Colacurcio, Fulgenzio ; Kauri, Massimo C. ; Moro, Anna R. ; De Novellis, Fedele</creatorcontrib><description>1.
1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50–300 mg i.m. monthly dose) for 12 months.
2.
2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population.
3.
3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1).
4.
4. A positive correlation was found between the administered dose and haloperidol plasma levels.
5.
5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1.
6.
6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/0278-5846(90)90061-K</identifier><identifier>PMID: 1967847</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult ; Antipsychotic Agents - pharmacokinetics ; Biological and medical sciences ; catatonic ; diagnosis ; disorganized ; Dose-Response Relationship, Drug ; EPSE ; extrapyramidal side-effects rating scale ; Female ; haioperidol decanoate ; haloperidol ; Haloperidol - analogs & derivatives ; Haloperidol - blood ; Haloperidol - pharmacokinetics ; Haloperidol - therapeutic use ; haloperidol decanoate ; HL-D ; Humans ; L/D ; level/dose ratio ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; not performed ; paranoid ; patient ; pharmacokinetics ; Pharmacology. Drug treatments ; plasma levels ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Recurrence ; schizophrenia ; Schizophrenia - blood ; Schizophrenia - drug therapy ; standard deviation ; undifferentiated ; years ; yrs</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 1990, Vol.14 (1), p.25-35</ispartof><rights>1990</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-e224ffec555df90aa8befdfe4ca60e712edb98f60d4f811baf988a47cfac8dc53</citedby><cites>FETCH-LOGICAL-c386t-e224ffec555df90aa8befdfe4ca60e712edb98f60d4f811baf988a47cfac8dc53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/027858469090061K$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6732205$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1967847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Altamura, Carlo A.</creatorcontrib><creatorcontrib>Colacurcio, Fulgenzio</creatorcontrib><creatorcontrib>Kauri, Massimo C.</creatorcontrib><creatorcontrib>Moro, Anna R.</creatorcontrib><creatorcontrib>De Novellis, Fedele</creatorcontrib><title>Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>1.
1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50–300 mg i.m. monthly dose) for 12 months.
2.
2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population.
3.
3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1).
4.
4. A positive correlation was found between the administered dose and haloperidol plasma levels.
5.
5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1.
6.
6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.</description><subject>Adult</subject><subject>Antipsychotic Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>catatonic</subject><subject>diagnosis</subject><subject>disorganized</subject><subject>Dose-Response Relationship, Drug</subject><subject>EPSE</subject><subject>extrapyramidal side-effects rating scale</subject><subject>Female</subject><subject>haioperidol decanoate</subject><subject>haloperidol</subject><subject>Haloperidol - analogs & derivatives</subject><subject>Haloperidol - blood</subject><subject>Haloperidol - pharmacokinetics</subject><subject>Haloperidol - therapeutic use</subject><subject>haloperidol decanoate</subject><subject>HL-D</subject><subject>Humans</subject><subject>L/D</subject><subject>level/dose ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>not performed</subject><subject>paranoid</subject><subject>patient</subject><subject>pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>plasma levels</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Recurrence</subject><subject>schizophrenia</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - drug therapy</subject><subject>standard deviation</subject><subject>undifferentiated</subject><subject>years</subject><subject>yrs</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVJSTdp_0ELOoSSHNxK_pDlHAoh5KMk0EtLj2J2NMIKsuVI3pT019fbXdJbTwPzPjO8PIy9l-KTFFJ9FmWri0bX6rQTZ50QShZ3r9hK6mVdl1IdsNUL8oYd5fwghJCVqA7ZoexUq-t2xX7eQogTJW9j4JYQxggzcT9y7FMcPfKMvf8dpz7R6OGcX_A8b-wzj47Lkg9xnPvMf_m551OAPAAP9EQhv2WvHYRM7_bzmP24vvp-eVvcf7v5enlxX2Cl1VxQWdbOETZNY10nAPSanHVUIyhBrSzJrjvtlLC101KuwXVaQ92iA9QWm-qYfdz9nVJ83FCezeAzUggwUtxk03ZKVKqSC1jvQEwx50TOTMkPkJ6NFGbr02xlma0s0wnz16e5W84-7P9v1gPZf0c7gUt-ss8hIwSXYESfXzDVVmUptjW_7LBFDT15SiajpxHJ-kQ4Gxv9_3v8AYQlkxA</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>Altamura, Carlo A.</creator><creator>Colacurcio, Fulgenzio</creator><creator>Kauri, Massimo C.</creator><creator>Moro, Anna R.</creator><creator>De Novellis, Fedele</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1990</creationdate><title>Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels</title><author>Altamura, Carlo A. ; Colacurcio, Fulgenzio ; Kauri, Massimo C. ; Moro, Anna R. ; De Novellis, Fedele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-e224ffec555df90aa8befdfe4ca60e712edb98f60d4f811baf988a47cfac8dc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>catatonic</topic><topic>diagnosis</topic><topic>disorganized</topic><topic>Dose-Response Relationship, Drug</topic><topic>EPSE</topic><topic>extrapyramidal side-effects rating scale</topic><topic>Female</topic><topic>haioperidol decanoate</topic><topic>haloperidol</topic><topic>Haloperidol - analogs & derivatives</topic><topic>Haloperidol - blood</topic><topic>Haloperidol - pharmacokinetics</topic><topic>Haloperidol - therapeutic use</topic><topic>haloperidol decanoate</topic><topic>HL-D</topic><topic>Humans</topic><topic>L/D</topic><topic>level/dose ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>not performed</topic><topic>paranoid</topic><topic>patient</topic><topic>pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>plasma levels</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Recurrence</topic><topic>schizophrenia</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - drug therapy</topic><topic>standard deviation</topic><topic>undifferentiated</topic><topic>years</topic><topic>yrs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Altamura, Carlo A.</creatorcontrib><creatorcontrib>Colacurcio, Fulgenzio</creatorcontrib><creatorcontrib>Kauri, Massimo C.</creatorcontrib><creatorcontrib>Moro, Anna R.</creatorcontrib><creatorcontrib>De Novellis, Fedele</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Altamura, Carlo A.</au><au>Colacurcio, Fulgenzio</au><au>Kauri, Massimo C.</au><au>Moro, Anna R.</au><au>De Novellis, Fedele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>1990</date><risdate>1990</risdate><volume>14</volume><issue>1</issue><spage>25</spage><epage>35</epage><pages>25-35</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>1.
1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50–300 mg i.m. monthly dose) for 12 months.
2.
2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population.
3.
3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p < 0.01) higher EPSE total scores compared to those with a duration of illness < 10 yrs (Group 1).
4.
4. A positive correlation was found between the administered dose and haloperidol plasma levels.
5.
5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1.
6.
6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>1967847</pmid><doi>10.1016/0278-5846(90)90061-K</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 1990, Vol.14 (1), p.25-35 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79603631 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Antipsychotic Agents - pharmacokinetics Biological and medical sciences catatonic diagnosis disorganized Dose-Response Relationship, Drug EPSE extrapyramidal side-effects rating scale Female haioperidol decanoate haloperidol Haloperidol - analogs & derivatives Haloperidol - blood Haloperidol - pharmacokinetics Haloperidol - therapeutic use haloperidol decanoate HL-D Humans L/D level/dose ratio Male Medical sciences Middle Aged Neuropharmacology not performed paranoid patient pharmacokinetics Pharmacology. Drug treatments plasma levels Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Recurrence schizophrenia Schizophrenia - blood Schizophrenia - drug therapy standard deviation undifferentiated years yrs |
| title | Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T15%3A59%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Haloperidol%20decanoate%20in%20chronic%20schizophrenia:%20A%20study%20of%2012%20months%20with%20plasma%20levels&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Altamura,%20Carlo%20A.&rft.date=1990&rft.volume=14&rft.issue=1&rft.spage=25&rft.epage=35&rft.pages=25-35&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/0278-5846(90)90061-K&rft_dat=%3Cproquest_cross%3E79603631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79603631&rft_id=info:pmid/1967847&rft_els_id=027858469090061K&rfr_iscdi=true |